Kearns-Sayre syndrome …

Neuromuscular Disorders

Updated 01.29.2024
Released 06.09.1993
Expires For CME 01.29.2027

Kearns-Sayre syndrome

Authors: Haluk Topaloglu MD, Didem Ardicli MD

See Contributor Disclosures

Editor: Nicholas E Johnson MD MSCI FAAN

Kearns-Sayre syndrome

In This Article

Quick Link

Introduction

Overview

Kearns-Sayre syndrome is a multisystem mitochondrial disease characterized by the obligate triad of onset before the age of 20, progressive external ophthalmoplegia, and pigmentary retinopathy plus at least one of the following: cardiac conduction block, cerebrospinal fluid protein greater than 100 mg/dl, and cerebellar ataxia. The disorder is usually caused by single large-scale deletions of mitochondrial DNA (mtDNA). The authors review the clinical features and molecular pathogenesis of this unusual disease and put special emphasis on reports on the heterogeneous response to growth hormone therapy in Kearns-Sayre syndrome.

Key points

	• Kearns-Sayre syndrome is a multisystemic disorder defined by the triad of chronic progressive external ophthalmoplegia, retinitis pigmentosa, and onset before 20 years of age.
	• Kearns-Sayre syndrome is usually a result of single, large-scale deletions (1.1 to 10 kb) of mitochondrial DNA.
	• Although Kearns-Sayre syndrome is typically sporadic, affected women with a large-scale deletion of mitochondrial DNA have a 4% to 11% risk of transmitting the mutation to a child.
	• In Kearns-Sayre syndrome, progressive cardiac conduction block is common and can be fatal; therefore, timely placement of a cardiac pacemaker can extend lifespan.

Historical note and terminology

In 1958, Kearns and Sayre reported two patients with the clinical triad of "retinitis pigmentosa, external ophthalmoplegia, and complete heart block" (33). For years, many physicians did not accept the existence of Kearns-Sayre syndrome; in the late 1960s, Dr. David Drachman lumped neurodegenerative disorders with progressive external ophthalmoplegia as "ophthalmoplegia plus" (16). In the late 1970s, Berenberg and colleagues reported five new patients and reviewed 30 literature cases with the triad of clinical features described by Kearns and Sayre. Berenberg and his colleagues further noted that the syndrome was sporadic, began before the age of 20 years, and was frequently accompanied by elevated cerebrospinal fluid protein (07). In 1983, Rowland and colleagues proposed a new clinical definition that included these features (61). In 1988, large-scale deletions of mitochondrial DNA were discovered as the underlying gene defect in Kearns-Sayre syndrome patients (27; 84; 28).

Clinical manifestations

Presentation and course

Multiple organ systems are affected in Kearns-Sayre syndrome; the predominant clinical features are found in the central nervous system, skeletal muscle, and heart (25). The syndrome is defined by the obligatory triad of (1) onset before the age of 20, (2) pigmentary retinopathy, and (3) progressive external ophthalmoplegia. In addition, at least one of the following must be present: (1) cardiac conduction block, (2) cerebrospinal fluid protein greater than 100 mg/dL, or (3) cerebellar ataxia (61).

Other clinical manifestations seen in the majority of Kearns-Sayre syndrome patients include short stature, sensorineural hearing loss, impaired intellect (intellectual disability, dementia, or both), and limb weakness. Neuropsychological testing of 15 patients with Kearns-Sayre syndrome revealed specific cognitive defects, particularly in visual construction, attention, and abstraction/flexibility, suggesting dysfunction of parietooccipital lobes and prefrontal cortex (09). A 2012 review of the psychiatric manifestations of mitochondrial disorders included four cases of Kearns-Sayre syndrome with bipolar disorder, cognitive impairment, psychotic disorder, or psychosomatic disorder (05). Facial dysmorphia has also been reported in Kearns-Sayre syndrome, attributed to abnormal neural crest cell development caused by mtDNA deletion (08).

Multiple endocrinopathies have been reported in Kearns-Sayre syndrome, including diabetes mellitus, hypoparathyroidism, hypothyroidism, hypogonadotropic hypogonadism, growth hormone deficiency, and adrenal insufficiency (02). The diabetes mellitus is not due to an insulin receptor defect but, rather, to insufficient insulin secretion (51). In a diabetic patient, autopsy revealed small pancreatic islets with absence of beta cells (53). Short stature in these patients has been attributed to a lack of growth hormone. Renal dysfunctions so far reported in Kearns-Sayre syndrome include renal failure, renal tubular acidosis, Bartter-like syndrome, and DeToni-Fanconi-Debré syndrome (19). Impaired mitochondrial function can also be associated with hypomagnesemia, most probably due to impairment of energy-dependent reabsorption of the magnesium cation in the kidney (77). Sensorimotor neuropathy is occasionally found in Kearns-Sayre syndrome. Heart involvement in Kearns-Sayre syndrome is variable, including atrioventricular block, dilated cardiomyopathy, bradycardia, myocardial scarring, ventricular arrhythmias, and sudden cardiac death (18). The most common cardiac involvement in Kearns-Sayre syndrome is atrioventricular block, which may develop at any time. Cardiomyopathy is less common than cardiac conduction block, but using cardiovascular magnetic resonance imaging, a pattern of diffuse intramural late-gadolinium-enhancement in the inferolateral segments of the left ventricle was identified in 10 out of 24 (42%) patients with chronic progressive external ophthalmoplegia or Kearns-Sayre syndrome (81; 21). Seizures and strokes are two major clinical features of myoclonus epilepsy with ragged-red fibers (MERFF) and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), but these features are uncommon in Kearns-Sayre syndrome patients (87). Strokes were attributed to cardiac emboli in at least two Kearns-Sayre syndrome patients (36; 54).

Onset is usually in childhood, with insidious ptosis, ophthalmoparesis, or both.

Ptosis and ophthalmoparesis

Bilateral ptosis and ocular divergence are evident. (Contributed by Dr. Michio Hirano.)

The ophthalmoparesis sometimes causes blurred or double vision. Weakness of the orbicularis oculi can lead to corneal ulcerations and in one patient caused corneal perforation (64). Corneal involvement with microcystic changes resembling Fuchs endothelial corneal dystrophy has been reported in 11 Kearns-Sayre syndrome cases (34). Vice versa, mitochondrial dysfunction has been reported in Fuchs endothelial corneal dystrophy, pointing to a role of energy metabolism in corneal diseases. Tauber and colleagues reported a patient with Kearns-Sayre syndrome and bilateral symmetrical exophthalmos, which might be secondary to ocular muscle wasting (75). Retinoschisis associated with Kearns-Sayre syndrome has been reported in a patient as a rare ophthalmic manifestation of the disease with unclear pathogenesis (11). Kearns-Sayre syndrome symptoms sometimes appear at the time of, or shortly after, a febrile illness. The disease progresses over years. If the cardiac conduction defect progresses to complete heart block, and a pacemaker is not inserted in time, the patient may die at a young age. Heart conduction block was found in 12 of 19 Kearns-Sayre syndrome patients in a Chinese cohort (83). Di Mambro and colleagues emphasized the progressive deterioration of the cardiac conduction system in Kearns-Sayre syndrome and the need for an electrocardiographic screening and a close follow-up to determine each patient’s arrhythmic risk (14). In their cohort consisting of 15 patients with Kearns-Sayre syndrome, left anterior fascicular block preceded right bundle branch block, and bi-fascicular block rapidly degenerated into advanced or complete atrioventricular block in 40%. Di Mambro and colleagues suggest a timely pacemaker implantation since bi-fascicular block development (14). Dysphagia is not uncommon; in a study of 12 patients, nine had documented cricopharyngeal achalasia (incomplete opening of the upper esophageal sphincter during the pharyngeal phase of swallowing) (35).

Pearson syndrome (sideroblastic anemia with pancreatic exocrine insufficiency) can precede Kearns-Sayre syndrome (50). This form of anemia can be fatal in infancy and has been associated with the same mitochondrial DNA defect seen in Kearns-Sayre syndrome (59). In addition to classical clinical phenotype, unusual features such as congenital anisocoria, severe caries, liver cysts, pituitary enlargement, desquamation of hands and feet, bone chondroma, aortic ectasia, dermoid cyst, and polyposis of nasal sinuses have also been reported recently in an adult patient with Kearns-Sayre syndrome (20).

Prognosis and complications

Cardiac conduction block is found in the majority of Kearns-Sayre syndrome patients. A 2012 review stresses the fact that, most frequently, syncope is the first clinical sign of the cardiac disease in Kearns-Sayre syndrome, whereas the underlying conduction defect may not always be easily identified in a 24-hour Holter ECG monitoring (76). Progression to a complete heart block can cause death; therefore, placement of a cardiac pacemaker can be a life-saving procedure (58). A literature review by Imamura and colleagues involving 112 patients with arrhythmia-associated Kearns-Sayre syndrome revealed that arrhythmia first manifested as bundle branch block, which then evolved into atrioventricular block and, in about 50% of the group, subsequently progressed to complete atrioventricular block (29). ECG should be performed every six months to one year to monitor for the development of a heart block.

The prognosis is difficult to determine without specific observation because of the variable tissue distribution of deleted mitochondrial DNA. Severe central nervous system involvement can cause debilitating ataxia, cognitive impairment, and spasticity. Retinal pigmentary degeneration may cause loss of vision, particularly loss of night (dim light) vision. Dysphagia due to pharyngeal and upper esophageal pathology is a common complication. A study of 69 patients with single mtDNA deletions suggested that neurologic complications were more likely when onset was before nine years of age and low when onset was after 20 years of age (06). In addition, the presence and proportion of mtDNA deletion in blood was also associated with development of neurologic manifestations. Brain MRI with diffusion tensor imaging may reveal early central nervous system involvement in Kearns-Sayre syndrome (17). In a cohort of 87 patients with single, large-scale mitochondrial DNA deletions, a variety of outcome measures such as COX-deficient fiber density, age-at-onset of symptoms, and progression of disease burden were significantly correlated with the size of the deletion, the deletion heteroplasmy level in skeletal muscle, and the location of the deletion within the genome (23). These authors also provide a web-based tool to model disease progression and burden in individual patients.

Clinical vignette

A young man was normal at birth and through early childhood but was noted at 8 years of age to have droopy eyelids. He was shorter and thinner than his school classmates, though performed well academically. At 13 years of age, he complained of premature fatigue with exercise. A pediatrician noted his short, thin appearance with ptosis and ophthalmoparesis. He was referred to a pediatric neurologist who noted a pigmentary retinopathy, but no ataxia. Cerebrospinal fluid analysis revealed elevated protein of 121 mg/dL (normal level is 45 mg/dL). An electrocardiogram showed a right bundle branch and left anterior fascicular blocks with a normal PR interval. Cardiac assessment detected a prolonged His-Purkinje conduction time and incipient atrioventricular node conduction abnormalities; a cardiac pacemaker was placed. A muscle biopsy was performed that revealed numerous ragged-red and cytochrome c oxidase-negative fibers; Southern blot analysis revealed a 7.0 kilobase deletion of the mitochondrial DNA in his muscles. He was treated with L-carnitine and coenzyme Q10. At 28 years of age, evaluation for increasing dyspnea on exertion revealed a cardiomyopathy. He was five feet six inches in height and weighed 85 pounds. He was treated with digoxin at a dosage of 0.125 mg once a day.

Biological basis

Etiology and pathogenesis

Large-scale deletions of mitochondrial DNA have been found in over 90% of Kearns-Sayre syndrome patients, with the most common deletion labeled as the “common 4977 bp deletion,” accounting for more than one third of cases (45). Most of the deletions have direct sequence repeats at the junction of the deleted segment of DNA (66; 43). Large-scale duplications of mitochondrial DNA have been found in some patients with Kearns-Sayre syndrome (52). In some patients with progressive external ophthalmoplegia, there was a point mutation at nucleotide 3243 of the mitochondrial DNA; this mutation is typically found in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome (44). In one patient who noted onset of symptoms at 22 years of age, but otherwise fulfilled clinical criteria for Kearns-Sayre syndrome, a G-to-A point mutation at nucleotide 3249 was identified (68). In a few cases, no mutation has been identified. Whole sequencing of the mitochondrial DNA genome in three patients with Kearns-Sayre syndrome revealed different classes, positions, lengths, and grades of heteroplasmy of the large-scale deletion, suggesting that size and heteroplasmy are related to the grade of this pathology (62).

The human disorder has been well modeled in a transmitochondrial mouse model (mito-miceΔ) displaying a heteroplasmic state for wild-type and deleted mtDNA (30). Mice with less than 10% deleted mtDNA remain normal throughout life. Mice with an initial deletion load between 10% and 50% manifest features of Kearns-Sayre syndrome at middle age, including lactic acidosis, heart block, renal failure, deafness, and memory impairment as well as male infertility. Interestingly, mice with more than 50% deleted mtDNA develop a Pearson syndrome-like phenotype; those who survive the first weeks show a subsequent decrease in deletion load and clinical remission, followed, however, by a new increase of deletion load and the multisystemic phenotype at middle age. As all mice in this model share the same nuclear genomic background, the level and dynamics of mtDNA deletion load in affected tissues seem to be the main determinant for onset and severity of the phenotype (32).

In a Caenorhabditis elegans model that stably expresses wild-type mtDNA and mtDNA with a 3.1-kilobase deletion, it was found that cells respond to OXPHOS dysfunction by activating the mitochondrial unfolded protein response (UPR(mt)), a transcriptional response mediated by the transcription factor ATFS-1 that promotes the recovery and regeneration of defective mitochondria. It seems that UPR(mt) activation caused by OXPHOS defects propagates or maintains the deleterious mtDNA in an attempt to recover OXPHOS activity by promoting mitochondrial biogenesis and dynamics. Interestingly, downregulation of ATFS-1 reduced the percentage of deleted mtDNA from 60% to 7% (41).

Almost all reported Kearns-Sayre syndrome patients have been sporadic, suggesting that the mitochondrial DNA rearrangements originate in the ovum or the embryo. Mitochondrial DNA is transmitted only through the mother; therefore, the mutant mitochondrial DNA cannot come from the sperm. Chen and colleagues demonstrated the presence of rearranged mitochondrial DNA molecules in human oocytes and found up to 0.1% of the so-called common deletion (10). These data support the hypothesis that the mitochondrial DNA deletions arise during germline development. Direct sequence repeats at the junctions of most deletions may contribute to the spontaneous generation of these mutations (66).

Clinical expression of the mutation depends on three factors: (1) mitochondrial DNA heteroplasmy, (2) mitochondrial DNA tissue distribution, and (3) tissue threshold. Each mitochondrion contains multiple copies of mitochondrial DNA, and each cell contains multiple mitochondria. Therefore, each cell can contain a variable number of normal and mutant mitochondrial DNA molecules, and this is termed “heteroplasmy.” The tissue distribution of mutant mitochondrial DNA is also heterogeneous (70). If a neonate has a large number of deleted mitochondrial DNA in the bone marrow, the baby will develop Pearson syndrome. If the infant survives the anemia because the bone marrow cells with a high percentage of deleted mitochondrial DNA are at a selective disadvantage and are gradually eliminated, then the child may develop Kearns-Sayre syndrome. Thus, the clinical phenotype depends on the tissue distribution of the mutation. In addition, the most metabolically active tissues are more susceptible to the deleterious effect of the mitochondrial DNA mutations (tissue threshold). Extraocular muscles seem to be particularly sensitive to the presence of mitochondrial DNA deletions.

Patients in whom mutant mitochondrial DNA segregates predominantly in muscles can have progressive external ophthalmoplegia as the only clinical manifestation or progressive external ophthalmoplegia plus myopathy affecting limbs, the oropharynx, or both. Some individuals have progressive external ophthalmoplegia and other manifestations of Kearns-Sayre syndrome but do not fulfill all the clinical criteria for the diagnosis of Kearns-Sayre syndrome (61). These cases have been called "progressive external ophthalmoplegia plus" or "Kearns-Sayre syndrome minus." Patients with Kearns-Sayre syndrome generally harbor higher proportions of mtDNA deletions in muscle than individuals with progressive external ophthalmoplegia (79; 42). In a study involving 155 Chinese patients with mitochondrial progressive ophthalmoplegia with large-scale mtDNA deletions, the size and locations of deletions were shown to be useful in differentiating chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome (86). Longer deletions and higher number of deleted genes encoding respiratory chain complex subunits and tRNA genes were observed in the Kearns-Sayre syndrome group.

Evidence from sequential muscle biopsies of Kearns-Sayre syndrome patients shows that the percentage of deleted mitochondrial DNA can increase in skeletal muscle (37), perhaps because the mutant mitochondrial DNA, being smaller, replicates more rapidly. This increase in deleted mitochondrial DNA may account for the delayed onset of symptoms and signs.

Analyses of respiratory chain enzymes in muscle have demonstrated variably severe combined defects of complexes containing mitochondrial DNA-encoded subunits. Cytochrome c oxidase (also called complex IV) seems to be particularly affected.

Muscle biopsies demonstrate mitochondrial abnormalities. Modified Gomori trichrome stain shows ragged-red fibers; the red stain in the subsarcolemmal regions of muscle fibers is due to accumulations of mitochondria.

Mitochondrial abnormalities (photomicrograph)

Modified Gomori trichrome stain in Kearns-Sayre syndrome shows ragged-red fibers; the red stain in the subsarcolemmal regions of muscle fibers is due to accumulations of mitochondria. (Contributed by Dr. Michio Hirano.)

Similarly, the succinate dehydrogenase histochemical stain reveals fibers equivalent to ragged-red fibers, with darker than normal reaction. Ultrastructural studies have confirmed the increased number of mitochondria, as well as morphologically abnormal mitochondria that sometimes contain paracrystalline inclusions. Cytochrome c oxidase histochemical stain shows individual muscle fibers with absent or reduced cytochrome c oxidase activity.

The central nervous system shows spongiform changes predominantly in the white matter, including neuronal degeneration, gliosis, and demyelination (47; 71). Mineral deposits of calcium and iron have been noted in and around blood vessels in the basal ganglia and thalamus. Vascular proliferation has also been described but without a consistent geographic pattern. Histological studies have revealed mitochondrial abnormalities in the cerebellar dentate nucleus, loss of Purkinje cells, spongiform degeneration of the cerebellar white matter, and disconnection of Purkinje cells at the dentate nucleus; these abnormalities may contribute to the cerebellar ataxia of Kearns-Sayre syndrome (73; 72). Analysis of brain tissue from three patients showed loss of myelin-associated glycoprotein and oligodendrocytes, whereas inflammation, neuronal loss, and axonal injury were minimal (39). This indicates that energetic failure can lead directly to CNS demyelination. Cerebral folate deficiency has been detected in patients with Kearns-Sayre syndrome and may contribute to cerebral white matter changes (03; 69). It has been suggested that the accumulation of mtDNA deletions in choroid plexus of Kearns-Sayre syndrome patients leads to an energetic defect of metabolite transport via the blood-brain barrier. The resulting deficiency of 5-methyltetrahydrofolate (5-MTHF) may directly compromise the methylation and stability of myelin. In a study, untargeted metabolomics analysis of two patients with Kearns-Sayre syndrome revealed increased levels of free sialic acid, sphingomyelin, and tau protein with low 5-methyltetrahydrofolate (5-MTHF) levels on CSF samples (63).

The high frequency of cardiac conduction block in Kearns-Sayre syndrome may be due to preferential accumulation of deleted mitochondrial DNA in the conduction system (46).

The pathophysiology whereby defects in mitochondrial DNA cause the histological and clinical features is not known. Alterations in respiratory chain complexes and energy metabolism are the main consequences of mtDNA deletions in Kearns-Sayre syndrome. In the last two decades, researches have been made to shed light on other pathological pathways. Cells containing mtDNA deletions showed signs of increased protein damage, inhibition of the ubiquitin-proteosome system, and induction of autophagy, which may contribute to the pathogenesis (01). Potential associated mechanisms include reactive oxygen species overproduction, protein synthesis inhibition, myelin vacuolation, demyelination, apoptosis, autophagy, and lipid raft involvement. In addition, the contributions of oligodendrocytes and astrocytes have been demonstrated (80).

Diagnostic workup

The screening of patients for Kearns-Sayre syndrome should begin with routine blood tests, including complete blood count, serum electrolytes, liver function tests, blood urea nitrogen, creatinine, lactate, and pyruvate. These tests may reveal sideroblastic anemia, or kidney or liver dysfunction. Elevated lactate and pyruvate at rest is common in Kearns-Sayre syndrome patients, and these values may increase dramatically after moderate exercise. The blood leukocyte DNA may be screened for mitochondrial DNA rearrangements, but mutations will be detected only in a minority of Kearns-Sayre syndrome patients, and are almost never found in patients with pure progressive external ophthalmoplegia.

ECG must be performed to screen for heart block. Lumbar puncture typically shows elevated cerebrospinal fluid protein (usually over 100 mg/dL), whereas pleocytosis is usually absent. Oligoclonal bands in the cerebrospinal fluid may be a nonspecific abnormality. Electromyography and nerve conduction studies are usually consistent with a myogenic process, although a neuropathy may also be present. Brain CT or MRI often reveals leukoencephalopathy, cerebral or cerebellar atrophy, or basal ganglia lesions (67; 78). A report characterizing the imaging patterns of mitochondrial leukodystrophies showed that patients with Kearns-Sayre syndrome predominantly have abnormalities in the subcortical white matter, globus pallidus, and substantia nigra (60). Early involvement of the subcortical white matter is highly characteristic of Kearns-Sayre syndrome, which may help in the differential diagnosis of the lysosomal and peroxisomal disorders. Proton MRI-spectroscopy features include low levels of N-acetyl aspartate in CNS and increased CSF lactate (04). Recently, Pasquini and colleagues reported different patterns of spinal cord involvement in 6 of 11 patients with Kearns-Sayre syndrome, including gray and white matter lesions (49).

Finally, muscle biopsy should be performed to confirm the diagnosis. Ragged-red fibers on modified Gomori trichrome stain are the hallmark histological feature. In addition, other features characteristic of abnormal mitochondria may be found. Mitochondrial enzyme activities can be measured in whole muscle homogenate or in isolated mitochondria. Muscle mitochondrial DNA should be screened by long-range polymerase chain reaction and by Southern blot analysis for the presence of deleted or duplicated mitochondrial DNA.

Management

No treatment for the genetic defect is currently available. Management is supportive and symptomatic; it includes treatment of complications: eyelid slings and surgical repair for ptosis, cochlear implants, and hearing aids can be used for sensorineural hearing loss and hormone replacement therapy for endocrinopathies.

Cardiac involvement in Kearns-Sayre syndrome requires comprehensive management and cardiac conduction block is a preventable cause of mortality. The College of Cardiology, American Heart Association, Heart Rhythm Society, and European Society of Cardiology guidelines recommend prophylactic pacemaker implantation for advanced atrioventricular block in Kearns-Sayre syndrome patients. Although, pacemaker implantation alone may not be effective enough to prevent sudden death, and an implantable cardioverter-defibrillator may also be required for selective cases. Imamura and colleagues reported a patient with Kearns-Sayre syndrome who developed polymorphic ventricular tachycardia, ventricular fibrillation, and QT prolongation who was treated with mexiletine and successfully managed with an implantable cardioverter-defibrillator (29). Heart transplantation due to dilated cardiomyopathy has been reported only in a few patients with Kearns-Sayre syndrome (15).

Coenzyme Q10 (50 to 100 mg three times a day) and L-carnitine (330 mg three times a day) have been used to improve mitochondrial function and have had anecdotal success. EPI-743 is a synthetic structurally modified analog of CoQ 10 in which the bis(methoxy) groups of the quinone have been replaced with bis-methyl groups, and the tail has three rather than 10 isoprenyl units. Double-blind, placebo-controlled, randomized clinical trials of EPI-743 are currently in progress for Kearns-Sayre syndrome https://clinicaltrials.gov/ct2/show/NCT01370447.

Promising results of the first mitochondrial augmentation therapy (MAT; using autologous CD34+ hematopoietic stem cells of the recipient enriched with normal mitochondria from his mother) on a 14-year-old patient with Kearns-Sayre syndrome have been reported. Marked improvement in both neurologic functions and metabolic status 7 months after treatment suggests that MAT may be a potential therapy for Kearns-Sayre syndrome (82). Data on the effect of mitochondrial augmentation therapy in six pediatric patients with single large-scale mtDNA deletion syndromes (including four patients with Pearson syndrome and two patients with Kearns-Sayre syndrome) showed some clinical improvement in aerobic functions and quality of life assessments (31).

Short stature in these patients has been attributed to lack of growth hormone (GH), but the response to growth hormone treatment is heterogeneous (56). In eight Kearns-Sayre syndrome patients, the mean improvement in height was from -3.9 to -2.9 standard deviation score (SDS), but two patients did not show growth improvement at all. The additional index patient in this report achieved a final adult height at -0.8 SDS (56).

In patients with severe dysphagia due to cricopharyngeal achalasia, myotomy can be helpful (35).

Endurance exercise training may improve exercise intolerance and quality of life. Resistance exercise training may increase muscle strength and may lower mutational burden in patients with mitochondrial DNA deletions. Both modes of exercise appear to be well tolerated. Kearns-Sayre syndrome patients should start their training at low intensity and duration. They should "listen to their body" and not exercise on days they have a fever or superimposed illness (74).

Preliminary data support the notion that folinic acid therapy might be useful in the treatment of Kearns-Sayre syndrome patients. In six patients treated with oral folinic acid at doses of 1 to 3 mg/kg/day for up to eight years, decreased 5-methyltetrahydrofolate levels in CSF recovered to normal values (three of three patients), and two of six patients improved neurologically (55). Absence of clinical and radiological response to folinic acid therapy in a patient with Kearns-Sayre syndrome is also reported (48). Early treatment with high-dose folinic acid therapy may be an option for the treatment of Kearns-Sayre syndrome, and a randomized trial seems warranted.

Because hypomagnesemia in Kearns-Sayre syndrome may contribute to neuromuscular irritability, seizures, and cardiac arrhythmias, magnesium should be supplemented in case of deficiency (77).

A more causal therapy approach is site-specific elimination of pathogenic human mtDNA mitochondrially targeted zinc finger nucleases. In a hybrid cell model harboring the common deletion, expression of these nucleases led to a reduction in deletion load, and subsequent repopulation of wild-type mtDNA restored mitochondrial respiratory function (22). This study constitutes proof-of-principle that, through heteroplasmy manipulation, delivery of site-specific nuclease activity to mitochondria can alleviate a severe biochemical phenotype in primary mitochondrial disease arising from deleted mtDNA species. Generation and evaluation of isogenic-induced pluripotent stem cells (iPSC) as a source of cell replacement therapies in patients with Kearns-Sayre syndrome has been reported (40).

References

01: Alemi M, Prigione A, Wong A, et al. Mitochondrial DNA deletions inhibit proteasomal activity and stimulate an autophagic transcript. Free Radic Biol Med 2007;42(1):32-43. PMID 17157191
02: Al-Gadi IS, Haas RH, Falk MJ, Goldstein A, McCormack SE. Endocrine disorders in primary mitochondrial disease. J Endocr Soc 2018;2(4):361-73. PMID 29594260
03: Allen RJ, DiMauro S, Coulter DL, Papadimitriou A, Rothenberg SP. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 1983;13:679-82. PMID 6881930
04: Alves CAPF, Gonçalves FG, Grieb D, Lucato LT, Goldstein AC, Zuccoli G. Neuroimaging of mitochondrial cytopathies. Top Magn Reson Imaging 2018;27(4):219-40. PMID 30086109
05: Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, Rosebush PI. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J Clin Psychiatry 2012;73(4):506-12. PMID 22579150
06: Aure K, Ogier de Baulny H, Laforet P, Jardel C, Eymard B, Lombés A. Chronic progressive ophthalmoplegia with large-scale mtDNA rearrangement: can we predict progression. Brain 2007;130:1516-24. PMID 17439982
07: Berenberg RA, Pellock JM, DiMauro S, et al. Lumping or splitting. "Ophthalmoplegia plus" or Kearns-Sayre syndrome. Ann Neurol 1977;1:37-43. PMID 889288
08: Berio A, Piazzi A, Traverso CE. Kearns-Sayre syndrome with facial and white matter extensive involvement: a (mitochondrial and nuclear gene related?) neurocristopathy? Pediatr Med Chir 2017;39(4):169. PMID 29502391
09: Bosbach S, Kornblum C, Schroder R, Wagner M. Executive and visuospatial deficits in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Brain 2003;126:1231-40. PMID 12690061
10: Chen X, Prosser R, Simonetti S, Sadlock J, Jagiello G, Schon EA. Rearranged mitochondrial genomes are present in human oocytes. Am J Hum Genet 1995;57:239-47. PMID 7668249
11: Chertkof J, Hufnagel RB, Blain D, Gropman AL, Brooks BP. Retinoschisis associated with Kearns-Sayre syndrome. Ophthalmic Genet 2020;41(5):497-500. PMID 32787478
12: Chinnery P, DiMauro S, Shanske S, et al. Risk of developing a mitochondrial DNA deletion disorder. Lancet 2004;364(9434):592-6. PMID 15313359
13: Desnuelle C, Pellissier J, Serratrice G, Pouget J, Turnbull D. Le syndrome de Kearns et Sayre: encéphalomyopathie mitochondriale par déficit de la chaine respiratoire. Rev Neurol 1989;145:842-50. PMID 2559448
14: Di Mambro C, Tamborrino PP, Silvetti MS, et al. Progressive involvement of cardiac conduction system in paediatric patients with Kearns–Sayre syndrome: how to predict occurrence of complete heart block and sudden cardiac death? Europace 2021;23:948-57. PMID 33336258
15: Di Nora C, Paldino A, Miani D, et al. Heart transplantation in Kearns-Sayre syndrome. Transplantation 2019; 103(12):3393-4. PMID 31335783
16: Drachman DA. Ophthalmoplegia plus: a classification of the disorders associated with progressive external ophthalmoplegia. In: Vinken PJ, Bruyn GW, Corsellis JA, editors. Handbook of clinical neurology. Vol 22. New York: Elsevier, 1975:203-16.
17: Duning T, Deppe M, Keller S, Mohammadi S, Schiffbauer H, Marziniak M. Diffusion tensor imaging in a case of Kearns-Sayre syndrome: striking brainstem involvement as a possible cause of oculomotor symptoms. J Neurol Sci 2009;281:110-2. PMID 19344916
18: Finsterer J. Cardiac disease in Kearns-Sayre syndrome requires comprehensive management. Cardiol Young 2019;(8):1118-9. PMID 31270000
19: Finsterer J, Scorza FA. Renal manifestations of primary mitochondrial disorders. Biomed Rep 2017;6(5):487-94. PMID 28515908
20: Finsterer J, Winklehner M, Stöllberger C, Hummel T. Unusual phenotype and disease trajectory in Kearns-Sayre syndrome. Case Rep Neurol Med 2020;2020:7368527. PMID 32181031
21: Florian A, Ludwig A, Stubbe-Dräger B, et al. Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. J Cardiovasc Magn Reson 2015;17:40. PMID 26001801
22: Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med 2014;6:458-66. PMID 24567072
23: Grady JP, Campbell G, Ratnaike T, et al. Disease progression in patients with single, large-scale mitochondrial DNA deletions. Brain 2014;137(Pt 2):323-34. PMID 24277717
24: Gupta SN, Marks HG. Spinocerebellar ataxia type 7 mimicking Kearns-Sayre syndrome: a clinical diagnosis is desirable. J Neurol Sci 2008;264:173-6. PMID 17720198
25: Hirano M, DiMauro S. Clinical features of mitochondrial myopathies and encephalomyopathies. In: Lane RJ, editor. Handbook of muscle disease. New York: Marcel Dekker, 1996;479-504.
26: Hirano M, Pitceathly RDS. Progressive external ophthalmoplegia. Handb Clin Neurol 2023;194:9-21. PMID 36813323
27: Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717-9. PMID 2830540
28: Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in mitochondrial myopathies: sequence analysis and possible mechanisms. Nucl Acids Res 1989;17:4465-9. PMID 2748329
29: Imamura T, Sumitomo N, Muraji S, et al. The necessity of implantable cardioverter defibrillators in patients with Kearns-Sayre syndrome - systematic review of the articles. Int J Cardiol 2019;279:105-11. PMID 30642644
30: Inoue K, Nakada K, Ogura A, et al. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat Genet 2000;26(2):176-81. PMID 11017072
31: Jacoby E, Bar-Yosef O, Gruber N, et al. Mitochondrial augmentation of hematopoietic stem cells in children with single large-scale mitochondrial DNA deletion syndromes. Sci Transl Med 2022;14(676):eabo3724. PMID 36542693
32: Katada S, Mito T, Ogasawara E, Hayashi J, Nakada K. Mitochondrial DNA with a large-scale deletion causes two distinct mitochondrial disease phenotypes in mice. G3 (Bethesda) 2013;3(9):1545-52. PMID 23853091
33: Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol 1958;60:280-9. PMID 13558799
34: Kim J, Medsinge A, Chauhan B, et al. Coenzyme Q10 in the treatment of corneal edema in Kearns-Sayre: is there an application in Fuchs endothelial corneal dystrophy? Cornea 2016;35(9):1250-4. PMID 27442316
35: Kornblum C, Broicher R, Walther E, et al. Cricopharyngeal achalasia is a common cause of dysphagia in patients with mtDNA deletions. Neurology 2001;56:1409-12. PMID 11376201
36: Kosinski C, Mull M, Lethen H, Topper R. Evidence for cardioembolic stroke in a case of Kearns-Sayre syndrome. Stroke 1995;26:1950-2. PMID 7570754
37: Larsson NG, Holme E, Kristiansson B, Oldfors A, Tulinius M. Progressive increase of the mutated mitochondrial DNA fraction in Kearns-Sayre syndrome. Pediatr Res 1990;28:131-6. PMID 2395603
38: Lauwers MH, Van Lersberghe C, Camu F. Inhalation anaesthesia and the Kearns-Sayre syndrome. Anaesthesia 1994;49:876-8. PMID 7802184
39: Lax NZ, Campbell GR, Reeve AK, et al. Loss of myelin-associated glycoprotein in Kearns-Sayre syndrome. Arch Neurol 2012;69(4):490-9. PMID 22491194
40: Lester Sequiera G, Srivastava A, Alagarsamy KN, Rockman-Greenberg C, Dhingra S. Generation and evaluation of isogenic iPSC as a source of cell replacement therapies in patients with Kearns Sayre syndrome. Cells 2021;10(3):568. PMID 33807701
41: Lin YF, Schulz AM, Pellegrino MW, Lu Y, Shaham S, Haynes CM. Maintenance and propagation of a deleterious mitochondrial genome by the mitochondrial unfolded protein response. Nature 2016;533(7603):416-9. PMID 27135930
42: Lopez-Gallardo E, Lopez-Perez MJ, Montoya J, Ruiz-Pesini E. CPEO and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion 2009;9:314-7. PMID 19410662
43: Mita S, Rizzuto R, Moraes CT, et al. Recombination via flanking direct repeats is a major cause of large-scale deletions of human mitochondrial DNA. Nucl Acids Res 1990;18:561-7. PMID 2308845
44: Moraes CT, Ciacci F, Silvestri G, et al. Atypical clinical presentations associated with the MELAS mutation at position 3243 of human mitochondrial DNA. Neuromusc Disord 1993;3:43-50. PMID 8392410
45: Moraes CT, DiMauro S, Zeviani M, et al. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 1989;320:1293-9. PMID 2541333
46: Muller-Hocker J, Jacob U, Seibel P. The common 4977 base pair deletion of mitochondrial DNA preferentially accumulates in the cardiac conduction system of patients with Kearns-Sayre syndrome. Mod Pathol 1998;11:295-301. PMID 9521479
47: Oldfors A, Fyhr IM, Larsson NG, Tulinius M. Neuropathology in Kearns-Sayre syndrome. Acta Neupathol 1990;80:541-6. PMID 2251912
48: Pardo Ruiz E, Maturana Martínez D, Vázquez López M, Ruiz Martín Y. Kearns-Sayre syndrome: Absence of clinical response to treatment with oral folinic acid. Neurologia 2019;34(9):618-20. PMID 28318733
49: Pasquini L, Guarnera A, Rossi-Espagnet MC, et al. Correction to: Spinal cord involvement in Kearns-Sayre syndrome: a neuroimaging study. Neuroradiology 2020;62(12):1725. PMID 33000314
50: Pearson H, Lobel J, Kocoshis S, et al. A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr 1979;95:976-84. PMID 501502
51: Piccolo G, Aschei M, Ricordi A, Banfi P, Lo Curto F, Fratino P. Normal insulin receptors in mitochondrial myopathies with ophthalmoplegia. J Neurol Sci 1989;94:163-72. PMID 2614464
52: Poulton J, Deadman ME, Gardiner RM. Duplications of mitochondrial DNA in mitochondrial myopathy. Lancet 1989;1:236-40. PMID 2563411
53: Poulton J, O'Rahilly S, Morten KJ, Clark A. Mitochondrial DNA, diabetes and pancreatic pathology in Kearns-Sayre syndrome. Diabetologia 1995;38:868-71. PMID 7556992
54: Provenzale JM, VanLandingham K. Cerebral infarction associated with Kearns-Sayre syndrome-related cardiomyopathy. Neurology 1996;46:826-8. PMID 8618693
55: Quijada-Fraile P, O'Callaghan M, Martín-Hernández E, et al. Follow-up of folinic acid supplementation for patients with cerebral folate deficiency and Kearns-Sayre syndrome. Orphanet J Rare Dis 2014;9:217. PMID 25539952
56: Quintos JB, Hodax JK, Gonzales-Ellis BA, Phornphutkul C, Wajnrajch MP, Boney CM. Efficacy of growth hormone therapy in Kearns-Sayre syndrome: the KIGS experience. J Pediatr Endocrinol Metab 2016;29(11):1319-24. PMID 27718492
57: Remes AM, Majamaa-Voltti K, Karppa M, et al. Prevalence of large-scale mitochondrial DNA deletions in an adult Finnish population. Neurology 2005;64(6):976-81. PMID 15781811
58: Rheuban K, Ayres N, Sellers T, DiMarco J. Near-fatal Kearns-Sayre syndrome. A case report and review of clinical manifestations. Clin Pediatr (Phila) 1983;22:822-5. PMID 8627817
59: Rotig A, Cormier V, Blanche S, et al. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest 1990;86:1601-8. PMID 2243133
60: Roosendaal SD, van de Brug T, Alves CA, et al. Imaging patterns characterizing mitochondrial leukodystrophies. AJNR Am J Neuroradiol 2021;42(7):1334-40. PMID 34255734
61: Rowland LP, Hays AP, DiMauro S, DeVivo DC, Behrens MT. Diverse clinical disorders associated with morphological abnormalities of mitochondria. In: Cerri C, Scarlato G, editors. Mitochondrial pathology in muscle diseases. Padua: Piccin Editore, 1983.
62: Saldana-Martínez A, Muñoz ML, Pérez-Ramírez G, et al. Whole sequence of the mitochondrial DNA genome of Kearns Sayre Syndrome patients: identification of deletions and variants. Gene 2019;10;688:171-81. PMID 30528267
63: Salvador CL, Oppebøen M, Vassli AØ, et al. Increased sphingomyelin and free sialic acid in cerebrospinal fluid of Kearns-Sayre syndrome: new findings using untargeted metabolomics. Pediatr Neurol 2023;143:68-76. PMID 37018879
64: Schmitz K, Lins H, Behrens-Baumann W. Bilateral spontaneous corneal perforation associated with complete external ophthalmoplegia in mitochondrial myopathy (Kearns-Sayre syndrome). Cornea 2003;22:267-70. PMID 12658098
65: Schnitzler E, Robertson W. Familial Kearns-Sayre syndrome. Neurology 1979;29:1172-4. PMID 572507
66: Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, DiMauro S. A direct repeat is a hotspot for large-scale deletions of human mitochondrial DNA. Science 1989;244:346-9. PMID 2711184
67: Seigel R, Seeger J, Gabrielsen T, Allen R. Computed tomography in oculocraniosomatic disease (Kearns-Sayre syndrome). Radiology 1979;130:159-64. PMID 758643
68: Seneca S, Verhelst H, De Meirleir L, et al. A new mitochondrial point mutation in the transfer RNA(Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch Neurol 2001;58:1113-8. PMID 11448301
69: Serrano M, Garcia-Silva MT, Martin-Hernandez E, et al. Kearns-Sayre syndrome: cerebral folate deficiency, MRI findings and new cerebrospinal fluid biochemical features. Mitochondrion 2010;10:429-32. PMID 20388557
70: Shanske S, Moraes CT, Lombes A, et al. Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology 1990;40:24-8. PMID 2296377
71: Sparaco M, Bonilla E, DiMauro S, Powers JM. Neuropathology of mitochondrial encephalomyopathies due to mitochondrial DNA defects. J Neuropathol Exp Neurol 1993;52:1-10. PMID 8426185
72: Tanji K, DiMauro S, Bonilla E. Disconnection of cerebellar Purkinje cells in Kearns-Sayre syndrome. J Neurol Sci 1999b;166(1):64-70. PMID 10465502
73: Tanji K, Vu TH, Schon EA, DiMauro S, Bonilla E. Kearns-Sayre syndrome: unusual pattern of expression of subunits of the respiratory chain in the cerebellar system. Ann Neurol 1999a;45(3):377-83. PMID 10072053
74: Tarnopolsky MA. Exercise as a therapeutic strategy for primary mitochondrial cytopathies. J Child Neurol 2014;29(9):1225-34. PMID 25008908
75: Tauber J, Polla DJ, Park S. Exophthalmos in Kearns-Sayre syndrome. J AAPOS 2019;23(5):295-7. PMID 31158487
76: van Beynum I, Morava E, Taher M, et al. Cardiac arrest in Kearns-Sayre syndrome. JIMD Rep 2012;2:7-10. PMID 23430846
77: Viering DH, de Baaij JH, Walsh SB, Kleta R, Bockenhauer D. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol 2017;32(7):1123-35. PMID 27234911
78: Wray SH, Provenzale JM, Johns DR, Thulborn KR. MR of the brain in mitochondrial myopathy. Am J Neuroradiol 1995;16:1167-73. PMID 7639148
79: Yamashita S, Nishino I, Nonaka I, Goto Y. Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions. J Hum Genet 2008;53:598-606. PMID 18414780
80: Yazdani M. Cellular and molecular responses to mitochondrial DNA deletions in Kearns-Sayre syndrome: some underlying mechanisms. Mol Neurobiol 2024. [Epub ahead of print] PMID 38224444
81: Yilmaz A, Gdynia HJ, Ponfick M, et al. Cardiovascular magnetic resonance imaging (CMR) reveals characteristic pattern of myocardial damage in patients with mitochondrial myopathy. Clin Res Cardiol 2012;101(4):255-61. PMID 22143423
82: Bar Yosef O, Jacoby E, Gruber N. Promising results for Kearns-Sayre syndrome of first in Man treatment by mitochondrial augmentation therapy. Neurology 2020;94(15 Supplement):457.
83: Yu M, Zhang Z, Wang QQ, et al. Clinical and brain magnetic resonance imaging features in a cohort of Chinese patients with Kearns-Sayre syndrome. Chin Med J (Engl) 2016;129(12):1419-24. PMID 27270536
84: Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988;38:1339-46. PMID 3412580
85: Zeviani M, Servidei S, Gellera C, Bertini E, DiMauro S, DiDonato S. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989;339:309-11. PMID 2725645
86: Zhao Y, Hou Y, Zhao X, et al. The clinical, myopathological, and genetic analysis of 155 Chinese mitochondrial ophthalmoplegia patients with mitochondrial DNA single large deletions. Mol Genet Genomic Med 2023;12(1):e2328. PMID 38018320
87: Zupanc M, Moraes CT, Shanske S, Langman C, Ciafaloni E, DiMauro S. Mitochondrial DNA deletion in patients with combined features of Kearns-Sayre and MELAS syndromes. Ann Neurol 1991;29:680-3. PMID 1892371

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Haluk Topaloglu MD

Dr. Topaloglu of Hacettepe Children's Hospital in Ankara, Turkey, has no relevant financial relationships to disclose.
See Profile
Didem Ardicli MD

Dr. Ardicli of Ankara Kecioren Research and Training Hospital has no relevant financial relationships to disclose.
See Profile

Editor

Nicholas E Johnson MD MSCI FAAN

Dr. Johnson of Virginia Commonwealth University received consulting fees and/or research grants from AMO Pharma, Avidity, Dyne, Novartis, Pepgen, Sanofi Genzyme, Sarepta Therapeutics, Takeda, and Vertex, consulting fees and stock options from Juvena, and honorariums from Biogen Idec and Fulcrum Therapeutics as a drug safety monitoring board member.
See Profile

Former Authors

Emma Ciafaloni MD FAAN
Thomas Klopstock MD and Michio Hirano MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Kearns-Sayre syndrome: 277.87
ICD-10: Kearns-Sayre syndrome: H49.8
OMIM: Kearns-Sayre syndrome: #530000

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Kearns-Sayre syndrome

Associated Disorders

Pearson syndrome
Progressive external ophthalmoplegia
Diabetes mellitus
DeToni-Fanconi-Debré syndrome

Differential Diagnosis

myasthenia gravis
oculopharyngeal myopathy
myotonic dystrophy
autosomal dominantly transmitted multiple deletions
mitochondrial encephalomyopathy lactic acidosis, and stroke-like episodes
- other mitochondrial myopathies with progressive external ophthalmoplegia

Also Relevant

Chronic progressive external ophthalmoplegia
Common retinopathies
Complex II deficiency
Horizontal gaze palsy
Mitochondrial disorders
- Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome
- Molecular diagnosis of neurogenetic disorders
- Nondominant hereditary ataxias

Kearns-Sayre syndrome …

Kearns-Sayre syndrome

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Toxic and nutritional deficiency optic neuropathies

Nystagmus

Third nerve palsy

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Drug-induced myasthenic syndromes

Kearns-Sayre syndrome

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Toxic and nutritional deficiency optic neuropathies

Nystagmus

Third nerve palsy

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Drug-induced myasthenic syndromes

This is an article preview.
Start a Free Account
to access the full version.